Windtree licenses cardio drugs to Lee's for up to $138M milestones; PM deals restructured

WINDTREE THERAPEUTICS INC /DE/

Lee's gets exclusive rights to istaroxime, rostafuroxin, SERCA2a activators in 14 Asian countries for heart failure and cardiogenic shock.
Windtree eligible for up to $3.1M in pre-development/regulatory milestones and $135.25M in sales milestones, plus low double-digit sublicense income.
Tiered royalties from low single-digit to low double-digit on net sales, subject to reduction by up to 50% under generic competition.
PM USA/PMPSA amendments: Windtree pays $500k fixed plus $1.4M milestones, extinguishes quarterly payments.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

WINDTREE THERAPEUTICS INC /DE/ entered into License, Development and Commercialization Agreement with Lee's Pharmaceutical (HK) Ltd. with Lee's Pharmaceutical (HK) Ltd. valued at up to $3.1 million in potential upfront pre-development, development, clinical, and regulatory miles (effective 2023-01-07).

Action: entry
Agreement: license
Counterparty: Lee's Pharmaceutical (HK) Ltd.
Value: up to $3.1 million in potential upfront pre-development, development, clinical, and regulatory miles
Effective: 2023-01-07

Exact text from the filing

On January 12, 2024 Windtree Therapeutics, Inc. (the “ Company ”) entered into a License, Development and Commercialization Agreement with Lee’s Pharmaceutical (HK) Ltd., a company organized under the laws of Hong Kong (“ Lee ’ s ”), effective as of January 7, 2023 (the “ Lee ’ s License Agreement ”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

WINDTREE THERAPEUTICS INC /DE/ filing history →

Source: SEC EDGAR

accession 0001437749-24-001469

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.